FXS patients have a repeat length exceeding 200 CGGs that generally leads to methylation of the repeat and the promoter region, resulting in silencing of FMR1 gene expression (Fu et al., 1991; Dominique Heitz et al., 1992; Tang et al., 2017). The gene discussed is FMR1; the disease is fragile X syndrome.